{
    "id": 22506,
    "fullName": "SMO A459V",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "SMO A459V does not lie within any known functional domains of the Smo protein (UniProt.org). A459V is predicted to confer a gain of function to the Smo protein as demonstrated by increased Smo activity and also confers resistance to Hedgehog inhibitors in cell culture (PMID: 25759019).",
            "references": [
                {
                    "id": 5520,
                    "pubMedId": 25759019,
                    "title": "Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759019"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6608,
        "geneSymbol": "SMO",
        "terms": [
            "SMO",
            "CRJS",
            "FZD11",
            "Gx",
            "SMOH"
        ]
    },
    "variant": "A459V",
    "createDate": "05/12/2016",
    "updateDate": "09/05/2018",
    "referenceTranscriptCoordinates": {
        "id": 123167,
        "transcript": "NM_005631",
        "gDna": "chr7:g.129209307C>T",
        "cDna": "c.1376C>T",
        "protein": "p.A459V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6293,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).",
            "molecularProfile": {
                "id": 23091,
                "profileName": "SMO A459V"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5520,
                    "pubMedId": 25759019,
                    "title": "Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759019"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6274,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Erivedge (vismodegib) induced growth inhibition in cell culture (PMID: 25759019).",
            "molecularProfile": {
                "id": 23091,
                "profileName": "SMO A459V"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5520,
                    "pubMedId": 25759019,
                    "title": "Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759019"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6287,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).",
            "molecularProfile": {
                "id": 23091,
                "profileName": "SMO A459V"
            },
            "therapy": {
                "id": 1428,
                "therapyName": "Sonidegib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5520,
                    "pubMedId": 25759019,
                    "title": "Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759019"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6282,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).",
            "molecularProfile": {
                "id": 23091,
                "profileName": "SMO A459V"
            },
            "therapy": {
                "id": 1587,
                "therapyName": "Taladegib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5520,
                    "pubMedId": 25759019,
                    "title": "Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759019"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23091,
            "profileName": "SMO A459V",
            "profileTreatmentApproaches": [
                {
                    "id": 18450,
                    "name": "SMO Inhibitor",
                    "profileName": "SMO A459V"
                },
                {
                    "id": 18449,
                    "name": "GLI1/2 inhibitor",
                    "profileName": "SMO A459V"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 123167,
            "transcript": "NM_005631",
            "gDna": "chr7:g.129209307C>T",
            "cDna": "c.1376C>T",
            "protein": "p.A459V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}